NeuroRX

, Volume 1, Issue 2, pp 263–272 | Cite as

Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington’s disease

Article

Summary

Trangenic mouse models and other screens are being used to identify potential therapeutic agents for use in clinical trials in Huntington’s disease (HD). The development of surrogate markers that can be used in clinical therapeutics is an active area of research. Because HD is relatively uncommon and only a portion of available subjects meet inclusion and exclusion criteria, therapeutic trials are limited by the availability of potential subjects as well as the relative insensitivity of the clinical measures used. Neuroimaging methods offer the potential to provide noninvasive, reproducible, and objective methods not only to better understand the disease process but also to follow in clinical studies to determine if a drug is effective in slowing down disease progression or perhaps even in delaying onset. Following is a review of the literature, which highlights the studies that have been published to date.

Key Words

Huntington’s disease neuroimaging MRI PET biomarkers MRS 

References

  1. 1.
    Kremer B, Goldberg P, Andrews SE et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats.N Engl J Med 330: 1401–1406, 1994.PubMedCrossRefGoogle Scholar
  2. 2.
    Duyao M, Ambrose C, Myers R. Trinucleotide repeat length: instability and age of onset in Huntington’s disease.Nat Genet 4: 387–392, 1993.PubMedCrossRefGoogle Scholar
  3. 3.
    Goldberg YP, Andrews SE, Theilmann J et al. Familial predisposition to recurrent mutations causing Huntington’s disease: genetic risk to sibs of sporadic cases.J Med Genet 30: 987–990, 1993.PubMedCrossRefGoogle Scholar
  4. 4.
    Nance M and the American College of Medical Genetics/American Society of Human Genetics Huntington’s Disease Genetic Testing Working Group. Laboratory guidelines for Huntington disease genetic testing.Am J Hum Genet 62: 1243–1247, 1998.CrossRefGoogle Scholar
  5. 5.
    The Huntington’ s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes.Cell 72: 971–983, 1993.CrossRefGoogle Scholar
  6. 6.
    Kieburtz K, MacDonald M, Shih C et al. Trinucleotide repeat length and progression of illness in Huntington’s disease.J Med Genet 31: 872–874, 1994.PubMedCrossRefGoogle Scholar
  7. 7.
    Feigin A, Kieburtz K, Bordwell K et al. Functional decline in Huntington’s disease.Mov Disord 10: 211–214, 1995.PubMedCrossRefGoogle Scholar
  8. 8.
    Vonsattel JP, DiFiglia M. Huntington disease.J Neuropathol Exp Neurol 57: 369–384, 1998.PubMedCrossRefGoogle Scholar
  9. 9.
    Hersch SM. Huntington’s disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.Curr Opin Neurol 16: 501–506, 2003.PubMedGoogle Scholar
  10. 10.
    Sapp E, Schwarz C, Chase K et al. Huntingtin localization in brains of normal and Huntington’s disease patients.Ann Neurol 42: 604–612, 1997.PubMedCrossRefGoogle Scholar
  11. 11.
    Persichetti F, Ambrose GM, Ge P et al. Normal and expanded Huntington’s disease gene alleles produce distinguishable proteins due to translation across the CAG repeat.Mol Med 1: 374–383, 1995.PubMedGoogle Scholar
  12. 12.
    Sharp AH, Loev SJ, Schilling G et al. Widespread expression of Huntington’s disease gene (IT15) protein product.Neuron 14: 1065–1074, 1995.PubMedCrossRefGoogle Scholar
  13. 13.
    Trottier Y, Devys D, Imbert G et al. Cellular localization of the Huntington’s disease protein and discrimination of the normal and mutated form.Nat Genet 10: 104–110, 1995.PubMedCrossRefGoogle Scholar
  14. 14.
    Zuccato C, Ciammola A, Rigamonti D et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease.Science 293: 493–498, 2001.PubMedCrossRefGoogle Scholar
  15. 15.
    Brinkman RR, Mezci MM, Theilmann J et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.Am J Hum Genet 60: 1202–1210, 1997.PubMedGoogle Scholar
  16. 16.
    Wellington CL, Brinkman RR, O’Kusky JR et al. Toward understanding the molecular pathology of Huntington’s disease.Brain Pathol 7: 979–1002, 1997.PubMedCrossRefGoogle Scholar
  17. 17.
    Davies SW, Turmaine M, Lozens BA et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.Cell 90: 537–548, 1997.PubMedCrossRefGoogle Scholar
  18. 18.
    Gutekunst CA, Li SH, Yi A et al. Nuclear and neuropil aggregates in Huntington’ s disease: relationship to neuropathology.J Neurosci 19: 2522–2534, 1999.PubMedGoogle Scholar
  19. 19.
    Reddy PH, Williams M, Huang HM et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.Nat Genet 20: 198–202, 1998.PubMedCrossRefGoogle Scholar
  20. 20.
    Andreassen OA, Dedeoglu A, Ferrante RJ et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease.Neurobiol Dis 8: 479–491, 2001.PubMedCrossRefGoogle Scholar
  21. 21.
    Andreassen OA, Ferrante RJ, Huang HM et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models in Huntington’s disease.Ann Neurol 50: 112–117, 2001.PubMedCrossRefGoogle Scholar
  22. 22.
    Andreassen OA, Ferrante RJ, Dedeoglu A et al. Lipoic acid improves survival in transgenic mouse models of Huntington’s disease.NeuroReport 12: 3371–3373, 2001.PubMedCrossRefGoogle Scholar
  23. 23.
    Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.Nat Med 6: 797–801, 2000.PubMedCrossRefGoogle Scholar
  24. 24.
    Dedeoglu A, Kubilus JK, Jeitner TM et al. Therapeutic effects of cystamine in a murine model of Huntington’ s disease.J Neurosci 22: 8942–8950, 2002.PubMedGoogle Scholar
  25. 25.
    Ferrante RJ, Kubilus JK, Lee JL et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice.J Neurosci 23: 9418–9427, 2003.PubMedGoogle Scholar
  26. 26.
    Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency.Mov Disord 11: 1–4, 1996.CrossRefGoogle Scholar
  27. 27.
    Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex.Annu Rev Neurosci 9: 357–381, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Aylward EH, Li Q, Stine OC et al. Longitudinal change in basal ganglia volume in patients with Huntington’ s disease.Neurology 48: 394–399, 1997.PubMedGoogle Scholar
  29. 29.
    Rosas HD, Goodman J, Chen YI et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat.Neurology 57: 1025–1028, 2001.PubMedGoogle Scholar
  30. 30.
    Aylward EH, Codori AM, Rosenblatt A et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease.Mov Disord 15: 552–560, 2000.PubMedCrossRefGoogle Scholar
  31. 31.
    Brandt J, Bylsma FW, Aylward EH et al. Impaired source memory in Huntington’s disease and its relation to basal ganglia atrophy.J Clin Exp Neuropsychol 17: 868–877, 1995.PubMedCrossRefGoogle Scholar
  32. 32.
    Rosas HD, Korosheta WJ, Chen YI et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.Neurology 60: 1615–1620, 2003.PubMedGoogle Scholar
  33. 33.
    Fischl B, Salut DH, Busa E et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.Neuron 33: 341–355, 2002.PubMedCrossRefGoogle Scholar
  34. 34.
    Ashburner J, Friston KJ. Why voxel-based morphometry should be used.Neuroimage 14: 1238–1243, 2001.PubMedCrossRefGoogle Scholar
  35. 35.
    Thieben MJ, Duggins AJ, Good CD et al. The distribution of structural neuropathology in pre-clinical Huntington’s disease.Brain 125: 1815–1828, 2002.PubMedCrossRefGoogle Scholar
  36. 36.
    Rosas HD, Liu AK, Hersch S et al. Regional and progressive thinning of the cortical ribbon in Huntington’ s disease.Neurology 58: 695–701, 2002.PubMedGoogle Scholar
  37. 37.
    Brandt J, Shpritz B, Codori AM et al. Neuropsychological manifestations of the genetic mutation for Huntington’s disease in presymptomatic individuals.J Int Neuropsychol Soc 8: 918–924, 2002.PubMedCrossRefGoogle Scholar
  38. 38.
    Paulsen JS, Zhad H, Stout JC et al. Clinical markers of early disease in persons near onset of Huntington’ s disease.Neurology 57: 658–662, 2001.PubMedGoogle Scholar
  39. 39.
    Lawrence AD, Sahakian BJ, Hodges JR et al. Executive and mnemonic functions in early Huntington’s disease.Brain 119: 1633–1645, 1996.PubMedCrossRefGoogle Scholar
  40. 40.
    Lawrence AD, Watkins LH, Sahakian BJ et al. Visual object and visuospatial cognition in Huntington’s disease: implications for information processing in corticostriatal circuits.Brain 123: 1349–1364, 2000.PubMedCrossRefGoogle Scholar
  41. 41.
    Jahanshahi M, Brown RG, Marsden CD. A comparative study of simple and choice reaction time in Parkinson’s, Huntington’ s and cerebellar disease.J Neurol Neurosurg Psychiatry 56: 1169–1177, 1993.PubMedCrossRefGoogle Scholar
  42. 42.
    Witjes-Ane MN, Vegter-van der Vlis M, van Vugt JP et al. Cognitive and motor functioning in gene carriers for Huntington’s disease: a baseline study.J Neuropsychiatry Clin Neurosci 15: 7–16, 2003.PubMedCrossRefGoogle Scholar
  43. 43.
    Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington’s disease.NeuroReport 13: 703–706, 2002.PubMedCrossRefGoogle Scholar
  44. 44.
    Aron AR, Schlaghecken F, Fletcher PC et al. Inhibition of sub-liminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington’s disease.Brain 126: 713–723, 2003.PubMedCrossRefGoogle Scholar
  45. 45.
    Kunig G, Leenders KL, Sanchez-Pernaute R et al. Benzodiazepine receptor binding in Huntington’s disease: [11C]flumazenil uptake measured using positron emission tomography.Ann Neurol 47: 644–648, 2000.PubMedCrossRefGoogle Scholar
  46. 46.
    Backman L, Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntinton’s disease and normal aging.Scand J Psychol 42: 287–296, 2001.PubMedCrossRefGoogle Scholar
  47. 47.
    Backman L, Robins-Wahlin TB, Lundin A et al. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes.Brain 120: 2207–2217, 1997.PubMedCrossRefGoogle Scholar
  48. 48.
    Lawrence AD, Weeks RA, Brooks DJ et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington’s disease.Brain 121: 1343–1355, 1998.PubMedCrossRefGoogle Scholar
  49. 49.
    Pavese N, Andrews TC, Brooks DJ et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study.Brain 126: 1127–1135, 2003.PubMedCrossRefGoogle Scholar
  50. 50.
    Ghilardi M, Ghez C, Dhawan V, Moeller J, Mentis M, Nakamura T et al. Patterns of regional brain activation associated with different forms of motor learning.Brain Res 871: 127–145, 2000.PubMedCrossRefGoogle Scholar
  51. 51.
    Feigin A, Ghilardi MF, Ghez CP et al. Increased cingulate activation during motor sequence learning in presymptomatic Huntington’s disease.Neurology 58(Suppl 3): A333-A334, 2002.Google Scholar
  52. 52.
    Carbon M, Feigin A, Ghilardi MF et al. Longitudinal changes in the relationship between striatal D2 receptor binding and brain activation in preclinical Huntington’s disease.Neurology 60(Suppl 1): A247-A248, 2003.Google Scholar
  53. 53.
    Hayden MR, Martin WR, Stoessl AJ et al. Positron emission tomography in the early diagnosis of Huntington’ s disease.Neurology 36: 888–894, 1986.PubMedGoogle Scholar
  54. 54.
    Kuhl DE, Phelps ME, Markham CH et al. Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan.Ann Neurol 12: 425–434, 1982.PubMedCrossRefGoogle Scholar
  55. 55.
    Kuwert T, Lange HW, Langen KJ et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease.Brain Res 113: 1405–1423, 1990.Google Scholar
  56. 56.
    Young AB, Penney JB, Starosta-Rubinstein S et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline.Ann Neurol 20: 296–303, 1986.PubMedCrossRefGoogle Scholar
  57. 57.
    Young AB, Penney JB, Starosta-Rubinstein S et al. Normal caudate glucose metabolism in persons at risk for Huntington’s disease.Arch Neurol 44: 254–257, 1987PubMedGoogle Scholar
  58. 58.
    Antonini A, Leenders KL, Spiegel R et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease.Brain 119: 2085–2095, 1996.PubMedCrossRefGoogle Scholar
  59. 59.
    Hayden MR, Hewitt J, Stoessl AJ et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington’s disease.Neurology 37: 1441–1447, 1987.PubMedGoogle Scholar
  60. 60.
    Kuwert T, Ganslandt T, Jansen P et al. Influence of size of regions of interest on PET evaluation of caudate glucose consumption.J Comput Assist Tomogr 16: 789–794, 1992.PubMedCrossRefGoogle Scholar
  61. 61.
    Mazziotta JC, Phelps ME, Pahl JJ et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’ s disease.N Engl J Med 316: 357–362, 1987.PubMedCrossRefGoogle Scholar
  62. 62.
    Feigin A, Fukuda M, Zgaljardic D et al. Metabolic brain networks in presymptomatic Huntington’s disease. Paper presented at the 15th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders, Chicago, 2001.Google Scholar
  63. 63.
    Turjanski N, Weeks R, Dolan R et al. Striatal D1 and D2 receptor binding in patients with Huntington’ s disease and other choreas. A PET study.Brain 118: 689–696, 1995.PubMedCrossRefGoogle Scholar
  64. 64.
    Weeks RA, Piccini P, Harding AE et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington’s disease.Ann Neurol 40: 49–54, 1996.PubMedCrossRefGoogle Scholar
  65. 65.
    Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length.Ann Neurol 43: 253–255, 1998.PubMedCrossRefGoogle Scholar
  66. 66.
    Andrews TC, Weeks RA, Turjanski N et al. Huntington’s disease progression. PET and clinical observations.Brain 122: 2353–2363, 1999.PubMedCrossRefGoogle Scholar
  67. 67.
    Hussey D, Stewart P, Houle S et al. [C-11]raclopride striatal binding potential as a measure of Huntington’s disease progression: implications for prospective neuroprotective studies.J Nucl Med 39(Suppl): 200P, 1998.Google Scholar
  68. 68.
    Storey E, Kowall NW, Finn SF et al. The cortical lesion of Huntington’s disease: further neurochemical characterization, and re-production of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex.Ann Neurol 32: 526–534, 1992.PubMedCrossRefGoogle Scholar
  69. 69.
    Ellison DW, Beal MF, Martin JB. Amino acid neurotransmitters in postmortem human brain analyzed by high performance liquid chromatography with electrochemical detection.J Neurosci Methods 19: 305–315, 1987.PubMedCrossRefGoogle Scholar
  70. 70.
    Jenkins BG, Rosas HD, Chen 4C et al. 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers.Neurology 50: 1357–1365, 1998.PubMedGoogle Scholar
  71. 71.
    Koroshetz WJ, Jenkins BG, Rosen BR et al. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10.Ann Neurol 41: 160–165, 1997.PubMedCrossRefGoogle Scholar
  72. 72.
    Hoang TQ, Bluml S, Dubowitz DJ et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington’s and Parkinson’s diseases.Neurology 50: 1033–1040, 1998.PubMedGoogle Scholar
  73. 73.
    Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A et al. Clinical correlation of striatal 1H MRS changes in Huntington’s disease.Neurology 53: 806–812, 1999.PubMedGoogle Scholar
  74. 74.
    Ferrante RJ, Andreassen OA, Jenkins BG et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease.J Neurosci 20: 4389–4397, 2000.PubMedGoogle Scholar
  75. 75.
    Lodi R, Schapira AH, Manners D et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and denta-torubropallidoluysian atrophy.Ann Neurol 48: 72–76, 2000.PubMedCrossRefGoogle Scholar
  76. 76.
    Ferrante RJ, Andreassen OA, Dedeoglu A et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease.J Neurosci 22: 1592–1599, 2002.PubMedGoogle Scholar
  77. 77.
    Hersch SM, Ferrante RJ. Neuropathology and pathophysiology of Huntington’s disease. In: Movement disorders. Neurologic principles and practice (Watts AL, Koller WC, eds), pp 503–518. Columbus, OH: McGraw-Hill, 1997.Google Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2004

Authors and Affiliations

  • H. D. Rosas
    • 1
    • 5
  • A. S. Feigin
    • 2
    • 3
  • Steven M. Hersch
    • 4
  1. 1.Center for Neuroimaging of Aging and Neurodegenerative DiseasesMassachusetts General Hospital (MGH)Charlestown
  2. 2.Center for Neurosciences, North Shore Long Island Jewish Research Institute, and the Department of NeurologyNorth Shore University HospitalManhasset
  3. 3.Department of NeurologyNew York University School of MedicineNew York
  4. 4.Massachusetts General Institute for Neurodegenerative DiseaseMGHCharlestown
  5. 5.Athinoula A. Martinos Center for Biomedical ImagingMGH/Harvard Medical SchoolCharlestown

Personalised recommendations